AstraZeneca: successful phase III study of Farxiga

(CercleFinance.com) - AstraZeneca announced on Tuesday that a Phase III trial of Farxiga has achieved its primary endpoint in patients suffering from cardiac insufficiency.


In clinical trials, the antidiabetic agent demonstrated a "significant" reduction in the number of cardiovascular deaths or worsening of cardiac insufficiency compared to placebo.

The trial was conducted on non-diabetic and type-2 diabetic patients.
According to the scientific literature, half of patients suffering from cardiac insufficiency have a life expectancy of under five years post-diagnosis.

The AstraZeneca share is up 1.8% at 7,411 pence on the London Stock Exchange on Tuesday morning after the release of this data, one of the best performers in the FTSE 100 index.


Copyright (c) 2019 CercleFinance.com. All rights reserved.